Get the Stockscreener App
92.38
0.50%
0.46
After Hours:
91.00
-1.38
-1.49%
Zimmer Biomet Holdings Inc stock is traded at $92.38, with a volume of 1.00M.
It is up +0.50% in the last 24 hours and up +0.12% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$91.92
Open:
$92.58
24h Volume:
1.00M
Relative Volume:
0.44
Market Cap:
$18.24B
Revenue:
$7.68B
Net Income/Loss:
$903.80M
P/E Ratio:
20.76
EPS:
4.45
Net Cash Flow:
$1.14B
1W Performance:
+0.23%
1M Performance:
+0.12%
6M Performance:
-14.49%
1Y Performance:
-18.51%
1-Day Range:
$91.97
$92.98
1-Week Range:
$89.24
$92.98
52-Week Range:
$89.24
$116.71
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
92.38 | 18.24B | 7.68B | 903.80M | 1.14B | 4.45 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Zimmer Biomet sued for violating Treace Medical patents related to bunion treatment - MSN
Highridge sells bone healing business to Avista - BioWorld MedTech
Treace Medical Concepts (TMCI) Sues Zimmer Biomet Over Patent Infringements - GuruFocus
Zimmer Biomet Facing Patent Infringement Lawsuit From Treace Medical - marketscreener.com
Treace Medical sues Zimmer Biomet over patent infringement - Investing.com Australia
Treace Medical sues Zimmer Biomet over patent infringement By Investing.com - Investing.com Nigeria
Zimmer Biomet faces patent suit from Treace Medical (TMCI) - Seeking Alpha
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology - The Manila Times
Treace Medical files patent infringement suit against Zimmer Biomet - TipRanks
Treace Medical Concepts Files Patent Infringement Suit Against Zimmer Biomet - marketscreener.com
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Zimmer Biomet Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 31, 2017ZBH - ACCESS Newswire
zimmer biomet shareholders approve stock incentive plan amendments By Investing.com - Investing.com South Africa
Rep. Robert Bresnahan, Jr. Sells Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares - Defense World
zimmer biomet shareholders approve stock incentive plan amendments - Investing.com
Zimmer Biomet Approves Amendments at Annual Meeting - TipRanks
Zimmer Biomet Holdings (NYSE:ZBH) Has Affirmed Its Dividend Of $0.24 - Yahoo Finance
Zimmer Biomet Holdings' (NYSE:ZBH) Dividend Will Be $0.24 - simplywall.st
Zimmer Biomet sets quarterly dividend at $0.24 per share By Investing.com - Investing.com South Africa
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Knee Replacement Market Detailed in New Research ReportZimmer Biomet, Stryker - openPR.com
Zimmer Biomet Keeps Quarterly Dividend at $0.24 a Share, Payable Around July 31 to Shareholders of Record on June 26 - marketscreener.com
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025 - GuruFocus
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025 | ZBH Stock News - GuruFocus
Zimmer Biomet sets quarterly dividend at $0.24 per share - Investing.com
Zimmer Biomet Q2 2025 Dividend: $0.24 Per Share Payable July 31Key Dates and Details - Stock Titan
Zacks Research Forecasts Weaker Earnings for Zimmer Biomet - Defense World
Zimmer Biomet Chairman, President and CEO Ivan Tornos Joins OREF Board of Trustees - Yahoo Finance
A Look Back at Surgical Equipment & ConsumablesDiversified Stocks’ Q1 Earnings: Zimmer Biomet (NYSE:ZBH) Vs The Rest Of The Pack - Yahoo Finance
Zacks Research Forecasts Reduced Earnings for Zimmer Biomet - Defense World
Zimmer Biomet names Kevin Thornal as group president, global biz - Medical Buyer
Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas - The Malaysian Reserve
Zimmer Biomet Holdings (ZBH) Appoints Kevin Thornal as Group Pre - GuruFocus
Orthopedic Oncology Market is Booming WorldwideStryker, Zimmer Biomet - openPR.com
Zimmer hires former Nevro CEO Kevin Thornal - Yahoo Finance
Zimmer Biomet Holdings (ZBH) Appoints Kevin Thornal as Group President - GuruFocus
Zimmer Biomet names new Group President for Americas By Investing.com - Investing.com South Africa
Former Nevro CEO joins Zimmer Biomet as group president - MassDevice
Hip Replacement Market is Booming WorldwideZimmer Biomet, Stryker - openPR.com
Zimmer Biomet Appoints Kevin Thornal As Group President, Global Businesses And The Americas - marketscreener.com
Zimmer Biomet Appoints Kevin Thornal as Group President - TipRanks
Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas | ZBH Stock News - GuruFocus
Zimmer Biomet names new Group President for Americas - Investing.com
Saudi Arabia Dental Implants Market Trends and Forecasts 2020-2024 & 2025-2030, Competitive Analysis of Masar Medical, Keydent, Zimmer Biomet, Dentsply Sirona, and Henry Schein - Yahoo
Zimmer Biomet Holdings (ZBH) Stock Analysis: Navigating a Potential 17.25% Upside in the Healthcare Sector - DirectorsTalk Interviews
Zimmer Biomet’s SWOT analysis: orthopedic giant’s stock navigates challenges By Investing.com - Investing.com Nigeria
Zimmer Biomet’s SWOT analysis: orthopedic giant’s stock navigates challenges - Investing.com
Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Malaysian Reserve
Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | ZBH Stock News - GuruFocus
ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues - TradingView
Zimmer Biomet Holdings, Inc. (ZBH): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Zimmer Biomet Stock Outlook: Is Wall Street Bullish or Bearish? - Nasdaq
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):